Pilot study of capecitabine combined with celecoxib (CapCel) for the treatment of far advanced metastatic breast cancer (MBC) patients (pts)
Alessandra Fabi(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), Paola Malaguti, Michele Stanislaw Milella(University of Verona), Paolo Carlini(National Cancer Institute), Isabella Sperduti(San Gallicano Hospital), Alain Gelibter(Policlinico Umberto I), Paola Papaldo(Cancer Institute (WIA)), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Alessandra Felici
Cited by 1
Related Papers
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168